

# **AI in Oncology Market by Player Type (Integrated Suite), Application (Drug Discovery, De Novo Drug Design, Diagnosis, Precision Medicine, Genomic), Technology (CNN, NLP), Cancer Type (Lung), End User (Hospitals, Pharma), & Region - Global Forecast to 2030**

<https://marketpublishers.com/r/A3C433378DD4EN.html>

Date: December 2024

Pages: 581

Price: US\$ 4,950.00 (Single User License)

ID: A3C433378DD4EN

## **Abstracts**

The global AI in Oncology market is projected to reach USD 11.52 billion by 2030 from USD 2.45 billion in 2024, at a CAGR of 29.4% from 2024 to 2030. The market's growth is fuelled by the growing demand for cost-effective cancer treatments & solutions, streamlining of the drug discovery process, rapid digitization of healthcare records and patient data, the growing volume of cancer cases, and regulatory compliance requirements.

In March 2024, the journal published by the American Cancer Society stated the following key points:

More than 80% of AI devices that are FDA-approved are used in cancer detection & diagnosis. These devices have applications in the following: pathology (19.7%), radiology (54.9), and radiation oncology (8.5%).

AI aided in decreasing the workload of radiologists in breast cancer screening by 30% and in comparison to healthcare professionals, AI maintained more accuracy.

AI combined with human evaluations improved cancer detection rates by 8% in various studies.

Precision medicine tools powered by AI contributed to the 33% decline in cancer mortality rates over the past 32 years by enabling better diagnoses, tailored treatments, and optimized clinical decision-making.

However, integration with existing healthcare systems, data privacy, and security constraints pose a significant challenge within this market.

“Machine learning held the largest share in technology type in the AI in oncology market in 2023.”

The AI in oncology market is segmented based on technology into machine learning, natural language processing (NLP), context-aware processing and computing, computer vision, and image analysis (including optical character recognition). The machine learning segment held the largest market share in 2023. Further, the machine learning segment includes deep learning (including convolutional neural networks (CNN), recurrent neural networks (RNN), generative adversarial networks (GAN), graph neural networks (GNN), others), supervised learning, reinforcement learning, unsupervised learning, other machine learning technologies. Among these, deep learning is the largest segment owing to its capability to analyze and process vast and complex datasets including medical images with improved efficiency. Within deep learning technologies such as CNNs are effective for image-based cancer detection, while RNNs and GANs are used to improve the temporal pattern analysis and data synthesis. Moreover, deep learning's scalability, adaptability and precision in analyzing and identifying the subtle patterns in cancer helped in improving the diagnosis, risk predictions and treatment optimization.

“By player type, the integrated solution segment is the largest and is also expected to register the fastest growth over the forecast period.”

By player type, the AI in oncology market is divided into niche/point solution providers (including platform & service), integrated suite/platform providers (including platform & service), technology providers (only software), and business process service providers. The integrated suite/platform providers segment accounts for the largest and is projected to be the fastest-growing segment over the forecast year. “By player type, the integrated solution segment is the largest and is also expected to register the fastest growth over the forecast period.” The growth is attributed to the fact that these providers offer comprehensive end-to-end solutions to streamline workflows across all

treatment sectors of cancer such as detection, diagnosis, monitoring, and treatment planning. Such platforms help to integrate technologies including NLP, computer vision, and machine learning resulting in better clinical decision-making and offering seamless data interoperability.

Moreover, integrated suite/platform helps in decreasing the need for multiple vendors as they are unified systems due to their scalability and flexibility which results in cost effective solution. This holistic approach drives adoption and fuels rapid growth.

“Asia Pacific is estimated to register the highest CAGR over the forecast period.”

The AI in Oncology market is segmented mainly into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The AI in oncology market in Asia Pacific is projected to register at the highest CAGR rate during the forecast period. The growth of this region is due to the development of healthcare infrastructure, and government initiatives to modernize and digitalize the healthcare industry particularly due to rising cancer cases, growth in minimally invasive cancer treatments, and to increase in the survival rate of cancer patients. Countries such as Japan, China, and India are focusing on developing cost-effective solutions in cancer care emphasizing the importance of AI-driven data management to handle sensitive patient information and ensure compliance with regulatory mandates for healthcare data standardization. Various key players and startups in the countries are promoting AI use in cancer such as Niramai, a Bangalore-based health tech startup, developed Thermalytix, an AI-driven breast cancer screening solution. The technology uses non-invasive, radiation-free thermal imaging and machine learning algorithms to detect breast cancer at an earlier stage compared to traditional methods. The solution is designed for all ages and ensures privacy, portability, and high accuracy. It is available in over 30 cities across 200+ hospitals in India and is expanding globally to different countries, thereby, transforming preventive cancer care.

Breakdown of supply-side primary interviews by company type, designation, and region:

By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)

By Designation: Directors (35%), Managers (40%), and Others (25%)

By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)

## List of Companies Profiled in the Report

Certara USA. (US)

Siemens Healthineers (Germany)

GE Healthcare (US)

ConcertAI (US)

Medtronic (Ireland)

F. Hoffmann-La Roche Ltd (Switzerland)

Oracle(US)

NVIDIA Corporation(US)

Koninklijke Philips N.V. (Netherlands)

PathAI, Inc. (US)

CureMetrix, Inc. (US)

Mindpeak GmbH (Germany)

Paige AI, Inc. (US)

Predictive Oncology (US)

Exscientia (UK)

Insilico Medicine (US)

Iktos (Paris)

Tempus (US)

Azra AI (US)

CureMatch, Inc. (US)

OncoLens (US)

Triomics (US)

Clinakos. (US)

Perthera, Inc (US)

Cellworks Group, Inc. (US)

biomy, Inc. (Japan)

## Research Coverage

This research report categorizes the AI in oncology market by player type [niche/point solution providers (including platform & service), integrated suite/platform providers (including platform & service), technology providers (only software), and business process service providers], by application [drug discovery {target identification & validation, lead identification & optimization, de novo drug design}, drug development {preclinical testing, predictive modeling for human trials, clinical trial optimization, adaptive trial design & monitoring}, diagnosis & early detection {imaging & radiology (mammography, computed tomography, magnetic resonance imaging (MRI), nuclear imaging (PET & SPECT), X-ray imaging, ultrasound, others), digital pathology & histopathology, liquid biopsy & biomarker detection, genetic risk prediction}, treatment planning & personalization {personalized treatment planning (precision medicine & genomic analysis, radiomics and radiogenomics, predictive models for treatment response, treatment recommendation systems), radiation therapy, chemotherapy, immunotherapy, targeted therapy (combination & dose optimization, AI-guided drug delivery), surgical planning & assistance (preoperative imaging and 3D modeling, intraoperative guidance and robotics, postoperative analysis & recovery)}, patient engagement & remote monitoring {symptom management & virtual assistance, remote patient monitoring, patient education & empowerment}, post-treatment surveillance & survivorship care {recurrence monitoring, long-term outcome prediction, mental health & support systems}, data management & analytics, other applications, by cancer type (solid tumors [including breast cancer lung cancer, prostate cancer, colorectal cancer,

brain tumors, and other tumors], hematologic malignancies (including leukemia, lymphoma, multiple myeloma, other hematologic malignancies), by technology [machine learning {deep learning (convolutional neural networks (CNN), recurrent neural networks (RNN), generative adversarial networks (GAN), graph neural networks (GNN), others), supervised learning, reinforcement learning, unsupervised learning, other machine learning technologies}, natural language processing (NLP), context-aware processing and computing, computer vision, image analysis (including optical character recognition)], by deployment [on-premises model, cloud-based model, and hybrid model], by end user [healthcare providers {hospitals & clinics, specialty centers, laboratories & diagnostic centers, others}, pharmaceutical & biotechnology companies, medical device/equipment companies, academic & research institutions, government & regulatory agencies, healthcare payers, and others}, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in oncology market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the AI in oncology market. Competitive analysis of upcoming startups in the AI in oncology market ecosystem is covered in this report.

### Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall AI in oncology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

Analysis of key drivers (supportive regulations, growing necessity to reduce healthcare costs, reduction in costs and improved operational efficiency with AI in oncology platforms, rising demand for streamlined clinical trials, technological advancements in AI algorithms, rising cancer prevalence globally), restraints (ensuring data security is a major concern for both patients and users, elevated costs associated with adoption of AI, resistance to adoption), opportunities (focus on personalized treatment plans, collaborative efforts, AI-driven drug

discovery), and challenges (limited availability of datasets, interoperability issues) influencing the growth of the AI in oncology market

**Solution Development/Innovation:** Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in oncology market

**Market Development:** Comprehensive information about lucrative markets – the report analyses the AI in oncology market across varied regions.

**Market Diversification:** Exhaustive information about new solutions, untapped geographies, recent developments, and investments in the AI in oncology market

**Competitive Assessment:** In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Siemens Healthineers (Germany), GE Healthcare (US), ConcertAI (US), Medtronic (Ireland), F. Hoffmann-La Roche Ltd (Switzerland), Oracle(US), NVIDIA Corporation(US), Koninklijke Philips N.V. (Netherlands), PathAI, Inc. (US), CureMetrix, Inc. (US), Mindpeak GmbH (Germany), Paige AI, Inc. (US), Predictive Oncology (US), Exscientia (UK), and Insilico Medicine (US), among others in AI in oncology market.



## Contents

### 1 INTRODUCTION

#### 1.1 STUDY OBJECTIVES

#### 1.2 MARKET DEFINITION

#### 1.3 STUDY SCOPE

##### 1.3.1 MARKET SEGMENTATION AND GEOGRAPHIC SPREAD

##### 1.3.2 INCLUSIONS AND EXCLUSIONS

##### 1.3.3 YEARS CONSIDERED

#### 1.4 CURRENCY CONSIDERED

#### 1.5 STAKEHOLDERS

### 2 RESEARCH METHODOLOGY

#### 2.1 RESEARCH DATA

##### 2.1.1 SECONDARY DATA

###### 2.1.1.1 Key data from secondary sources

##### 2.1.2 PRIMARY DATA

###### 2.1.2.1 Primary sources

###### 2.1.2.1.1 Key data from primary sources

###### 2.1.2.1.2 Key industry insights

###### 2.1.2.2 Breakdown of primary interviews

#### 2.2 MARKET ESTIMATION METHODOLOGY

#### 2.3 MARKET SIZE ESTIMATION

#### 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION

#### 2.5 RESEARCH ASSUMPTIONS

##### 2.5.1 MARKET SIZING ASSUMPTIONS

##### 2.5.2 OVERALL STUDY ASSUMPTIONS

#### 2.6 RISK ASSESSMENT

#### 2.7 RESEARCH LIMITATIONS

##### 2.7.1 METHODOLOGY-RELATED LIMITATIONS

##### 2.7.2 SCOPE-RELATED LIMITATIONS

### 3 EXECUTIVE SUMMARY

### 4 PREMIUM INSIGHTS

#### 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS AI IN ONCOLOGY MARKET

*AI in Oncology Market by Player Type (Integrated Suite), Application (Drug Discovery, De Novo Drug Design, Dia...*



4.2 AI IN ONCOLOGY MARKET, BY REGION

4.3 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL AND COUNTRY

4.4 AI IN ONCOLOGY MARKET, BY COUNTRY

4.5 AI IN ONCOLOGY MARKET: DEVELOPED MARKETS VS. EMERGING MARKETS

## **5 MARKET OVERVIEW**

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.1.1 Increasing incidence of cancer disease

5.2.1.2 Growing need for early detection and diagnosis

5.2.1.3 Advancements in precision cancer treatment

5.2.1.4 Support from regulatory authorities

5.2.1.5 Increasing investments and funding

5.2.2 RESTRAINTS

5.2.2.1 High initial costs

5.2.2.2 Data integrity and algorithm validation

5.2.2.3 Integration with existing systems

5.2.3 OPPORTUNITIES

5.2.3.1 Radiomics and imaging analysis

5.2.3.2 Clinical trial optimization

5.2.3.3 Personalized treatment plans

5.2.3.4 Integration of multi-omics data

5.2.4 CHALLENGES

5.2.4.1 Limited availability of datasets

5.2.4.2 Data privacy and security

5.3 ECOSYSTEM ANALYSIS

5.4 CASE STUDY ANALYSIS

5.4.1 SIEMENS HEALTHINEERS IMPLEMENTED SYNGO.VIA RT IMAGE SUITE POWERED BY NVIDIA GPU-BASED SHERLOCK AI SUPERCOMPUTER

5.4.2 AI IN ONCOLOGY FOR PERSONALIZED TREATMENT PLANNING

5.4.3 PERSONALIZED OUTREACH FOR ONCOLOGISTS WITH TAKEDA'S AI SOLUTION

5.5 VALUE CHAIN ANALYSIS

5.6 PORTER'S FIVE FORCES ANALYSIS

5.6.1 BARGAINING POWER OF SUPPLIERS

5.6.2 BARGAINING POWER OF BUYERS

- 5.6.3 THREAT OF SUBSTITUTES
- 5.6.4 THREAT OF NEW ENTRANTS
- 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.7 REGULATORY LANDSCAPE
  - 5.7.1 NORTH AMERICA
  - 5.7.2 EUROPE
  - 5.7.3 ASIA PACIFIC
  - 5.7.4 MIDDLE EAST & AFRICA
  - 5.7.5 LATIN AMERICA
  - 5.7.6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.8 PATENT ANALYSIS
  - 5.8.1 PATENT PUBLICATION TRENDS FOR AI IN ONCOLOGY
  - 5.8.2 JURISDICTION ANALYSIS
  - 5.8.3 MAJOR PATENTS IN AI IN ONCOLOGY MARKET
- 5.9 TECHNOLOGY ANALYSIS
  - 5.9.1 KEY TECHNOLOGIES
    - 5.9.1.1 Machine learning
    - 5.9.1.2 Natural language processing
    - 5.9.1.3 Computer vision
  - 5.9.2 COMPLEMENTARY TECHNOLOGIES
    - 5.9.2.1 High-performance computing
    - 5.9.2.2 Next-generation sequencing
    - 5.9.2.3 Digital twins
    - 5.9.2.4 Real-world evidence/real-world data
  - 5.9.3 ADJACENT TECHNOLOGIES
    - 5.9.3.1 Cloud computing
    - 5.9.3.2 Theranostics
    - 5.9.3.3 Augmented and virtual reality
- 5.10 INDUSTRY TRENDS
  - 5.10.1 SHIFT TOWARD PERSONALIZED ONCOLOGY
  - 5.10.2 EXPANSION OF AI-BASED CLINICAL TRIALS
- 5.11 PRICING ANALYSIS
  - 5.11.1 INDICATIVE PRICING OF AI IN ONCOLOGY SOFTWARE, BY DEPLOYMENT MODEL
  - 5.11.2 AVERAGE SELLING PRICE OF AI IN ONCOLOGY PLATFORMS, BY REGION (2023)
- 5.12 KEY CONFERENCES AND EVENTS, 2025
- 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA

#### 5.13.1 KEY STAKEHOLDERS

#### 5.13.2 BUYING CRITERIA

### 5.14 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS

#### 5.15 END USER ANALYSIS

##### 5.15.1 UNMET NEEDS

##### 5.15.2 END USER EXPECTATIONS

### 5.16 INVESTMENT AND FUNDING SCENARIO

### 5.17 IMPACT OF GENERATIVE AI ON AI IN ONCOLOGY MARKET

#### 5.17.1 KEY USE CASES

#### 5.17.2 CASE STUDIES OF GENERATIVE AI IMPLEMENTATION

5.17.2.1 Case Study 1: Accelerated drug discovery with Generative AI and streamlined workflows

#### 5.17.3 IMPACT OF GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS

##### 5.17.3.1 Pharmaceutical research and development market

##### 5.17.3.2 Radiology and medical imaging market

##### 5.17.3.3 Healthcare delivery systems market

#### 5.17.4 USER READINESS AND IMPACT ASSESSMENT

##### 5.17.4.1 User readiness

###### 5.17.4.1.1 Use A: Healthcare providers

###### 5.17.4.1.2 User B: Pharmaceutical & biotechnology companies

##### 5.17.4.2 Impact assessment

###### 5.17.4.2.1 User A: Healthcare providers

###### 5.17.4.2.2 User B: Pharmaceutical & biotechnology companies

## 6 AI IN ONCOLOGY MARKET, BY TECHNOLOGY

### 6.1 INTRODUCTION

### 6.2 MACHINE LEARNING

#### 6.2.1 DEEP LEARNING

6.2.1.1 Need to streamline clinical workflows, reduce delays, and improve patient outcomes to drive market

##### 6.2.1.2 Convolutional neural networks

##### 6.2.1.3 Recurrent neural networks

##### 6.2.1.4 Generative adversarial networks

##### 6.2.1.5 Graph neural networks

##### 6.2.1.6 Others

#### 6.2.2 SUPERVISED LEARNING

6.2.2.1 Surge in demand for accurate predictions and tailored treatments to drive

market

### 6.2.3 REINFORCEMENT LEARNING

6.2.3.1 Extensive use in drug discovery to drive market

### 6.2.4 UNSUPERVISED LEARNING

6.2.4.1 Ability to perform complex tasks and uncover potential drug candidates to drive market

### 6.2.5 OTHER MACHINE LEARNING TECHNOLOGIES

## 6.3 NATURAL LANGUAGE PROCESSING

6.3.1 EMERGING DEVELOPMENTS IN ONCOLOGY CARE TO DRIVE MARKET

## 6.4 CONTEXT-AWARE PROCESSING AND COMPUTING

6.4.1 ABILITY TO OPTIMIZE CLINICAL WORKFLOWS TO DRIVE MARKET

## 6.5 COMPUTER VISION

6.5.1 ELEVATED DEMAND FOR PRECISION MEDICINE TO DRIVE MARKET

## 6.6 IMAGE ANALYSIS

6.6.1 AUTOMATION OF COMPLEX IMAGING TASKS TO DRIVE MARKET

# 7 AI IN ONCOLOGY MARKET, BY APPLICATION

## 7.1 INTRODUCTION

## 7.2 DRUG DISCOVERY

### 7.2.1 TARGET IDENTIFICATION & VALIDATION

7.2.1.1 Emphasis on avoiding last-stage failure in drug discovery to boost growth

### 7.2.2 HIT IDENTIFICATION & PRIORITIZATION

7.2.2.1 Need for large-scale data analysis in HTS screening to drive adoption

### 7.2.3 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION

7.2.3.1 AI-driven lead generation to improve selectivity and binding mechanisms

### 7.2.4 LEAD OPTIMIZATION

7.2.4.1 Need to accelerate make-design-test cycles and high possibility of clinical drug failure to spur market

### 7.2.5 CANDIDATE SELECTION & VALIDATION

7.2.5.1 Candidate selection and validation to facilitate early drug discovery

## 7.3 DRUG DEVELOPMENT

### 7.3.1 PRECLINICAL TESTING

7.3.1.1 Need to identify risks and optimize candidates to boost growth

### 7.3.2 PREDICTIVE MODELING FOR HUMAN TRIALS

7.3.2.1 Need for leveraging AI for accurate dose selection and safety assessments to boost growth

### 7.3.3 CLINICAL TRIAL OPTIMIZATION

7.3.3.1 Need to enhance trial efficiency and outcomes with AI-driven insights to

propel market

#### 7.3.4 ADAPTIVE TRIAL DESIGN & MONITORING

7.3.4.1 AI-driven adaptive trial design & monitoring help improve flexibility and success rates

### 7.4 DIAGNOSIS & EARLY DETECTION

#### 7.4.1 IMAGING & RADIOLOGY

##### 7.4.1.1 Mammography

7.4.1.1.1 Need for accurate diagnosis of breast cancer to propel market

##### 7.4.1.2 Computed tomography (CT)

7.4.1.2.1 Need for early diagnosis of solid tumors in lungs, liver, and brain to drive growth

##### 7.4.1.3 Magnetic resonance imaging (MRI)

7.4.1.3.1 Need for optimizing imaging and enhancing tumor detection by integrating AI into MRI to propel demand

##### 7.4.1.4 Nuclear imaging

7.4.1.4.1 Need for empowering AI-enhanced PET and SPECT imaging for precision oncology to drive growth

##### 7.4.1.5 X-ray Imaging

7.4.1.5.1 Integrating AI-powered X-rays to automate detection of lung nodules to boost market

##### 7.4.1.6 Ultrasound

7.4.1.6.1 Focus on integrating AI with ultrasound imaging to boost growth

##### 7.4.1.7 Other imaging modalities

#### 7.4.2 DIGITAL PATHOLOGY & HISTOPATHOLOGY

7.4.2.1 Focus on examining tissue samples to diagnose diseases to boost market

#### 7.4.3 LIQUID BIOPSY & BIOMARKER DETECTION

7.4.3.1 Advancements in non-invasive diagnostic technologies to propel growth

#### 7.4.4 GENETIC RISK PREDICTION

7.4.4.1 Increased awareness of people regarding hereditary cancer risk to encourage growth

### 7.5 TREATMENT PLANNING & PERSONALIZATION

#### 7.5.1 PERSONALIZED TREATMENT PLANNING

##### 7.5.1.1 Precision medicine & genomic analysis

7.5.1.1.1 Need for adopting personalized therapies to improve treatment response to boost growth

##### 7.5.1.2 Radiomics & radiogenomics

7.5.1.2.1 Emphasis on optimizing radiomics and radiogenomics for disease characterization to propel demand

##### 7.5.1.3 Predictive models for treatment response

7.5.1.3.1 Adoption of predictive modeling to analyze genetic information to improve growth

7.5.1.4 Treatment recommendation systems

7.5.1.4.1 Need for enhancing treatment decisions with data-driven insights to propel growth

7.5.2 RADIATION THERAPY

7.5.2.1 Need for effective tumor targeting to boost growth

7.5.3 CHEMOTHERAPY

7.5.3.1 Focus on optimizing chemotherapy for targeted treatment and risk prediction to boost segmental growth

7.5.4 IMMUNOTHERAPY

7.5.4.1 Use of immunotherapy for personalized and effective cancer care to boost growth

7.5.5 TARGETED THERAPY

7.5.5.1 Combination & dose optimization

7.5.5.1.1 Need for enhancing personalized dosing to augment segment growth

7.5.5.2 AI-guided drug delivery

7.5.5.2.1 Emphasis on achieving robust AI-powered drug delivery system to drive market

7.5.6 SURGICAL PLANNING & ASSISTANCE

7.5.6.1 Preoperative imaging & 3D modeling

7.5.6.1.1 AI-driven 3D models for enhanced oncology care

7.5.6.2 Intraoperative guidance and robotics

7.5.6.2.1 Focus on integrating robotic surgery to enhance precision in treatment to drive market

7.5.6.3 Postoperative analysis & recovery

7.5.6.3.1 Emphasis on enhancing AI in postoperative care to drive demand

7.6 PATIENT ENGAGEMENT & REMOTE MONITORING

7.6.1 SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE

7.6.1.1 Symptom management & virtual assistance tools are beneficial for chronic disease management

7.6.2 REMOTE PATIENT MONITORING

7.6.2.1 Need for AI-enhanced, real-time monitoring to augment growth

7.6.3 PATIENT EDUCATION & EMPOWERMENT

7.6.3.1 Improved health literacy and engagement with AI-curated insights

7.7 POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE

7.7.1 RECURRENCE MONITORING

7.7.1.1 Need to improve cancer surveillance and accurate recurrence detection and prognosis to drive market

## 7.7.2 LONG-TERM OUTCOME PREDICTION

7.7.2.1 Need for personalized care plans and chronic side-effect management to augment market

## 7.7.3 MENTAL HEALTH & SUPPORT SYSTEMS

7.7.3.1 Prioritizing mental health support in cancer care to augment segmental growth

## 7.8 DATA MANAGEMENT & ANALYTICS

7.8.1 INTEGRATION OF GENOMIC AND CLINICAL DATA TO ACCELERATE DEMAND FOR AI-POWERED ANALYTICS

## 7.9 OTHER APPLICATIONS

# 8 AI IN ONCOLOGY MARKET, BY CANCER TYPE

## 8.1 INTRODUCTION

## 8.2 SOLID TUMORS

8.2.1 RISING PREVALENCE OF SOLID TUMORS TO BOOST NEED FOR AI-DRIVEN INNOVATIONS

8.2.2 BREAST CANCER

8.2.3 LUNG CANCER

8.2.4 PROSTATE CANCER

8.2.5 COLORECTAL CANCER

8.2.6 BRAIN TUMOR

8.2.7 OTHER SOLID TUMORS

## 8.3 HEMATOLOGIC MALIGNANCIES

8.3.1 RISING CASES OF BLOOD CANCER TO DRIVE MARKET

8.3.2 LEUKEMIA

8.3.3 LYMPHOMA

8.3.4 MULTIPLE MYELOMA

8.3.5 OTHER HEMATOLOGIC MALIGNANCIES

## 8.4 OTHER CANCER TYPES

# 9 AI IN ONCOLOGY MARKET, BY END USER

## 9.1 INTRODUCTION

## 9.2 HEALTHCARE PROVIDERS

9.2.1 NEED FOR IMPROVED DIAGNOSTIC ACCURACY, PERSONALIZED TREATMENT PLANNING, AND ENHANCED WORKFLOW EFFICIENCY TO BOOST MARKET

9.2.2 HOSPITALS & CLINICS



### 9.2.3 SPECIALTY CENTERS

### 9.2.4 LABORATORIES & DIAGNOSTIC CENTERS

### 9.2.5 OTHER HEALTHCARE PROVIDERS

## 9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

### 9.3.1 NEED TO LEVERAGE AI FOR ACCELERATED ONCOLOGY DRUG DISCOVERY AND CLINICAL TRIALS TO BOOST GROWTH

## 9.4 MEDICAL DEVICE/ EQUIPMENT COMPANIES

## 9.5 ACADEMIC & RESEARCH INSTITUTIONS

## 9.6 GOVERNMENT & REGULATORY AGENCIES

## 9.7 HEALTHCARE PAYERS

## 9.8 OTHER END USERS

## 10 AI IN ONCOLOGY MARKET, BY PLAYER TYPE

### 10.1 INTRODUCTION

### 10.2 NICHE/POINT SOLUTION PROVIDERS

#### 10.2.1 NICHE/POINT SOLUTION PROVIDERS ACCELERATE CANCER DRUG DISCOVERY AND DEVELOPMENT

### 10.3 INTEGRATED SUITE/PLATFORM PROVIDERS

#### 10.3.1 INTEGRATED SUITE/PLATFORM PROVIDERS REDUCE NEED FOR MULTIPLE VENDORS AND ACCELERATE WORKFLOWS

### 10.4 TECHNOLOGY PROVIDERS

#### 10.4.1 DEMAND FOR IMPROVED ONCOLOGY WORKFLOWS TO DRIVE MARKET

### 10.5 BUSINESS PROCESS SERVICE PROVIDERS

#### 10.5.1 FOCUS ON OPTIMIZING NON-CLINICAL ONCOLOGY WORKFLOWS TO PROPEL MARKET GROWTH

## 11 AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL

### 11.1 INTRODUCTION

### 11.2 CLOUD-BASED MODEL

#### 11.2.1 NEED FOR ADVANCED CANCER RESEARCH AND TREATMENT TO BOOST USE OF CLOUD-BASED AI PLATFORMS

### 11.3 ON-PREMISES MODEL

#### 11.3.1 NEED FOR ENHANCED DATA SECURITY AND COMPLIANCE TO PROPEL ADOPTION OF ON-PREMISES MODEL

### 11.4 HYBRID MODEL

#### 11.4.1 NEED FOR ENHANCING SCALABILITY AND DATA SECURITY IN DIAGNOSTICS TO DRIVE USE OF HYBRID-BASED AI PLATFORMS

## 12 AI IN ONCOLOGY MARKET, BY REGION

### 12.1 INTRODUCTION

### 12.2 NORTH AMERICA

#### 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

#### 12.2.2 US

##### 12.2.2.1 Rising number of clinical trials and drug discovery to drive market

#### 12.2.3 CANADA

12.2.3.1 Pharmaceutical giants advancing innovation and expanding access to clinical trials to fuel market

### 12.3 EUROPE

#### 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

#### 12.3.2 GERMANY

##### 12.3.2.1 Advanced healthcare system and collaborative efforts to boost market

#### 12.3.3 UK

##### 12.3.3.1 Government support for developing new AI platforms to drive innovation

#### 12.3.4 FRANCE

##### 12.3.4.1 Growing R&D pipeline for oncology trials to drive market

#### 12.3.5 ITALY

##### 12.3.5.1 Favorable regulatory scenarios to propel AI adoption in oncology

#### 12.3.6 SPAIN

##### 12.3.6.1 Established network of research centers to propel market

#### 12.3.7 REST OF EUROPE

### 12.4 ASIA PACIFIC

#### 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

#### 12.4.2 CHINA

##### 12.4.2.1 Increasing healthcare expenditure to drive demand for oncology solutions

#### 12.4.3 INDIA

12.4.3.1 Growing cancer burden and healthcare disparities to fuel adoption of AI in oncology

#### 12.4.4 JAPAN

##### 12.4.4.1 Aging population and rising cancer rates to drive growth

#### 12.4.5 REST OF ASIA PACIFIC

### 12.5 LATIN AMERICA

#### 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

#### 12.5.2 BRAZIL

##### 12.5.2.1 Rising cases of breast cancer to support market growth

#### 12.5.3 MEXICO

12.5.3.1 Use of AI in pediatric cancer treatment and chemotherapy complications to fuel market growth

12.5.4 REST OF LATIN AMERICA

12.6 MIDDLE EAST & AFRICA

12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

12.6.2 GCC COUNTRIES

12.6.2.1 Growing cancer cases and increasing clinical trials to drive growth

12.6.3 REST OF MIDDLE EAST & AFRICA

## **13 COMPETITIVE LANDSCAPE**

13.1 INTRODUCTION

13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS

13.3 REVENUE ANALYSIS OF KEY PLAYERS

13.4 MARKET SHARE ANALYSIS

13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023

13.5.1 STARS

13.5.2 EMERGING LEADERS

13.5.3 PERVASIVE PLAYERS

13.5.4 PARTICIPANTS

13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023

13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023

13.6.1 PROGRESSIVE COMPANIES

13.6.2 RESPONSIVE COMPANIES

13.6.3 DYNAMIC COMPANIES

13.6.4 STARTING BLOCKS

13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023

13.7 COMPANY VALUATION AND FINANCIAL METRICS

13.8 BRAND/SOFTWARE COMPARISON

13.9 COMPETITIVE SCENARIO

13.9.1 PRODUCT LAUNCHES & ENHANCEMENTS

13.9.2 DEALS

13.9.3 EXPANSIONS

13.9.4 OTHER DEVELOPMENTS

## **14 COMPANY PROFILES**

14.1 KEY PLAYERS

#### 14.1.1 NVIDIA CORPORATION

14.1.1.1 Business overview

14.1.1.2 Products/Solutions offered

14.1.1.3 Recent developments

14.1.1.3.1 Deals

14.1.1.4 MnM view

14.1.1.4.1 Right to win

14.1.1.4.2 Strategic choices

14.1.1.4.3 Weaknesses and competitive threats

#### 14.1.2 GE HEALTHCARE

14.1.2.1 Business overview

14.1.2.2 Products/Solutions offered

14.1.2.3 Recent developments

14.1.2.3.1 Product launches & approvals

14.1.2.3.2 Deals

14.1.2.4 MnM view

14.1.2.4.1 Right to win

14.1.2.4.2 Strategic choices

14.1.2.4.3 Weaknesses and competitive threats

#### 14.1.3 SIEMENS HEALTHINEERS AG

14.1.3.1 Business overview

14.1.3.2 Products/Solutions offered

14.1.3.3 Recent developments

14.1.3.3.1 Product launches & approvals

14.1.3.3.2 Deals

14.1.3.3.3 Expansions

14.1.3.4 MnM view

14.1.3.4.1 Right to win

14.1.3.4.2 Strategic choices

14.1.3.4.3 Weaknesses and competitive threats

#### 14.1.4 F. HOFFMANN-LA ROCHE LTD

14.1.4.1 Business overview

14.1.4.2 Products/Solutions offered

14.1.4.3 Recent developments

14.1.4.3.1 Product launches & approvals

14.1.4.3.2 Deals

14.1.4.4 MnM view

14.1.4.4.1 Right to win

14.1.4.4.2 Strategic choices

- 14.1.4.4.3 Weaknesses and competitive threats
- 14.1.5 INSILICO MEDICINE
  - 14.1.5.1 Business overview
  - 14.1.5.2 Products/Solutions offered
  - 14.1.5.3 Recent developments
  - 14.1.5.4 MnM view
    - 14.1.5.4.1 Right to win
    - 14.1.5.4.2 Strategic choices
    - 14.1.5.4.3 Weaknesses and competitive threats
- 14.1.6 CONCERTAI
  - 14.1.6.1 Business overview
  - 14.1.6.2 Products/Solutions offered
  - 14.1.6.3 Recent developments
    - 14.1.6.3.1 Product launches & approvals
    - 14.1.6.3.2 Deals
- 14.1.7 MEDTRONIC
  - 14.1.7.1 Business overview
  - 14.1.7.2 Products/Solutions offered
  - 14.1.7.3 Recent developments
    - 14.1.7.3.1 Product launches & approvals
    - 14.1.7.3.2 Deals
- 14.1.8 ORACLE
  - 14.1.8.1 Business overview
  - 14.1.8.2 Products/Solutions offered
  - 14.1.8.3 Recent developments
    - 14.1.8.3.1 Product launches & approvals
    - 14.1.8.3.2 Deals
- 14.1.9 KONINKLIJKE PHILIPS N.V.
  - 14.1.9.1 Business overview
  - 14.1.9.2 Products/Solutions offered
  - 14.1.9.3 Recent developments
    - 14.1.9.3.1 Deals
- 14.1.10 PREDICTIVE ONCOLOGY
  - 14.1.10.1 Business overview
  - 14.1.10.2 Products/Solutions offered
  - 14.1.10.3 Recent developments
    - 14.1.10.3.1 Product launches & approvals
    - 14.1.10.3.2 Deals
- 14.1.11 EXSCIENCIA

- 14.1.11.1 Business overview
- 14.1.11.2 Products/Solutions offered
- 14.1.11.3 Recent developments
  - 14.1.11.3.1 Product launches & approvals
  - 14.1.11.3.2 Deals
  - 14.1.11.3.3 Expansions
  - 14.1.11.3.4 Other developments
- 14.1.12 PATHAI, INC.
  - 14.1.12.1 Business overview
  - 14.1.12.2 Products/Solutions offered
  - 14.1.12.3 Recent developments
    - 14.1.12.3.1 Product launches & approvals
    - 14.1.12.3.2 Deals
- 14.1.13 CUREMETRIX, INC.
  - 14.1.13.1 Business overview
  - 14.1.13.2 Products/Solutions offered
  - 14.1.13.3 Recent developments
    - 14.1.13.3.1 Other developments
- 14.1.14 MINDPEAK GMBH
  - 14.1.14.1 Business overview
  - 14.1.14.2 Products/Solutions offered
  - 14.1.14.3 Recent developments
    - 14.1.14.3.1 Product launches & approvals
    - 14.1.14.3.2 Deals
    - 14.1.14.3.3 Other developments
- 14.1.15 PAIGE AI, INC.
  - 14.1.15.1 Business overview
  - 14.1.15.2 Products/Solutions offered
  - 14.1.15.3 Recent developments
    - 14.1.15.3.1 Product launches & approvals
    - 14.1.15.3.2 Deals
    - 14.1.15.3.3 Other developments
- 14.1.16 TEMPUS AI, INC.
  - 14.1.16.1 Business overview
  - 14.1.16.2 Products/Solutions offered
  - 14.1.16.3 Recent developments
    - 14.1.16.3.1 Product launches & approvals
    - 14.1.16.3.2 Deals
    - 14.1.16.3.3 Expansions

14.1.16.3.4 Other developments

#### 14.1.17 IKTOS

14.1.17.1 Business overview

14.1.17.2 Products/Solutions offered

14.1.17.3 Recent developments

14.1.17.3.1 Deals

14.1.17.3.2 Other developments

#### 14.2 OTHER PLAYERS

14.2.1 AZRA AI

14.2.2 CUREMATCH, INC.

14.2.3 ONCOLENS

14.2.4 TRIOMICS

14.2.5 CLINAKOS

14.2.6 PERTHERA, INC.

14.2.7 CELLWORKS GROUP, INC.

14.2.8 BIOMY, INC.

### 15 APPENDIX

15.1 DISCUSSION GUIDE

15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

15.3 CUSTOMIZATION OPTIONS

15.4 RELATED REPORTS

15.5 AUTHOR DETAILS



## I would like to order

Product name: AI in Oncology Market by Player Type (Integrated Suite), Application (Drug Discovery, De Novo Drug Design, Diagnosis, Precision Medicine, Genomic), Technology (CNN, NLP), Cancer Type (Lung), End User (Hospitals, Pharma), & Region - Global Forecast to 2030

Product link: <https://marketpublishers.com/r/A3C433378DD4EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A3C433378DD4EN.html>